Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T-Cell Engager OM336 for Desensitization of Kidney Transplant Candidates

NCT07789431 is registered in ClinicalTrials.gov with Medical University of Vienna as lead sponsor.

NCT NCT07789431
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07789431 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Phase IIa Trial Exploring the Safety, Tolerability, and Efficacy of the T-Cell Engager OM336 for Desensitization of Kidney Transplant Candidates
Lead sponsor
Medical University of Vienna
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
September 1, 2030
Enrollment
12 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

highly sensitized patients awaiting kidney transplant